Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)
Amgen Inc. announced a dividend of $2.38 per share for the third quarter of 2025. The Board of Directors approved this decision, which is set to benefit all shareholders on record as of the close of business on August 22, 2025. The dividend will be disbursed on September 12, 2025.
About Amgen’s Commitment and Innovations
Based in Thousand Oaks, California, Amgen is recognized for its pioneering work in biotechnology, having played a significant role in the industry’s establishment over four decades ago. The company is dedicated to discovering, developing, manufacturing, and delivering innovative medicines aimed at combating some of the world’s most challenging diseases.
Amgen’s extensive portfolio includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions. The company has continually pushed the boundaries of medical science, utilizing advanced technology and human genetic data to enhance its offerings. In 2024, Amgen received accolades such as being named one of the “World’s Most Innovative Companies” by Fast Company and recognized as one of “America’s Best Large Employers” by Forbes.
Future Outlook and Strategic Developments
The company’s growth strategy includes a robust pipeline of products, underscoring its commitment to advancing healthcare solutions. Notably, Amgen’s collaboration with firms like BeOne Medicines Ltd. and Kyowa Kirin Co., Ltd. aims to enhance the performance of its existing treatments, including Otezla (apremilast).
While Amgen remains optimistic about its future, it acknowledges the inherent risks and uncertainties involved in its operations. This includes potential challenges related to regulatory developments, market competition, and supply chain dynamics. The company emphasizes that actual results may vary significantly from projections, influenced by various factors such as changes in market conditions and the regulatory environment.
For more information about Amgen and its initiatives, the company encourages interested parties to visit its website at Amgen.com and follow its social media channels for updates.
As Amgen continues to innovate and expand its reach in the biotechnology sector, the declared dividend signals its commitment to delivering value to its shareholders while advancing crucial medical research and development.
